{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:11:24Z","timestamp":1793985084357,"version":"4.8.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-024-00811-3","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T06:04:11Z","timestamp":1726725851000},"page":"1515-1533","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b\/2 clinical trial and correlative analyses"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2214-9450","authenticated-orcid":false,"given":"Divij","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0618-4798","authenticated-orcid":false,"given":"Natalia","family":"Baran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tushar D.","family":"Bhagat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Skwarska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Lodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5271-3235","authenticated-orcid":false,"given":"Tianyu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4219-7708","authenticated-orcid":false,"given":"Veronica A.","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8882-7146","authenticated-orcid":false,"given":"Gowri","family":"Poigaialwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinitha M.","family":"Kuruvilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergej","family":"Konoplev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanisha","family":"Gordon-Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kith","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Aluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7439-5138","authenticated-orcid":false,"given":"G. Lavender","family":"Hackman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sovira","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6201-9298","authenticated-orcid":false,"given":"Meghan","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon R.","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Busquets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul Singh","family":"Rathore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6309-9472","authenticated-orcid":false,"given":"Michael R.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Demo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav S.","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srabani","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beamon","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mason","family":"Spodek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Thiruthuvanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Will","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Steidl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George D.","family":"Tippett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7679-6453","authenticated-orcid":false,"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-6119","authenticated-orcid":false,"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9892-9832","authenticated-orcid":false,"given":"Tapan","family":"Kadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5990-9548","authenticated-orcid":false,"given":"Steven","family":"Kornblau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval G.","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Naqvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-2482","authenticated-orcid":false,"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7230-0307","authenticated-orcid":false,"given":"Stefano","family":"Tiziani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5408-1673","authenticated-orcid":false,"given":"Amit","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-2212","authenticated-orcid":false,"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"811_CR1","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/nrc.2016.71","volume":"16","author":"BJ Altman","year":"2016","unstructured":"Altman, B. J., Stine, Z. E. & Dang, C. V. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat. Rev. Cancer 16, 619\u2013634 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"811_CR2","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1158\/2159-8290.CD-12-0345","volume":"2","author":"JR Cantor","year":"2012","unstructured":"Cantor, J. R. & Sabatini, D. M. Cancer cell metabolism: one hallmark, many faces. Cancer Discov. 2, 881\u2013898 (2012).","journal-title":"Cancer Discov."},{"key":"811_CR3","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/nature11706","volume":"491","author":"A Schulze","year":"2012","unstructured":"Schulze, A. & Harris, A. L. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 491, 364\u2013373 (2012).","journal-title":"Nature"},{"key":"811_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1126\/science.123.3191.309","volume":"123","author":"O Warburg","year":"1956","unstructured":"Warburg, O. On the origin of cancer cells. Science 123, 309\u2013314 (1956).","journal-title":"Science"},{"key":"811_CR5","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/1535-7163.MCT-13-0870","volume":"13","author":"MI Gross","year":"2014","unstructured":"Gross, M. I. et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol. Cancer Ther. 13, 890\u2013901 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"811_CR6","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3109\/07357907.2014.907419","volume":"32","author":"M Goto","year":"2014","unstructured":"Goto, M. et al. Importance of glutamine metabolism in leukemia cells by energy production through TCA cycle and by redox homeostasis. Cancer Invest. 32, 241\u2013247 (2014).","journal-title":"Cancer Invest."},{"key":"811_CR7","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1158\/1078-0432.CCR-18-3223","volume":"25","author":"MA Gregory","year":"2019","unstructured":"Gregory, M. A. et al. Targeting glutamine metabolism and redox state for leukemia therapy. Clin. Cancer Res. 25, 4079\u20134090 (2019).","journal-title":"Clin. Cancer Res."},{"key":"811_CR8","first-page":"4077","volume":"45","author":"G Dranoff","year":"1985","unstructured":"Dranoff, G., Elion, G. B., Friedman, H. S., Campbell, G. L. & Bigner, D. D. Influence of glutamine on the growth of human glioma and medulloblastoma in culture. Cancer Res. 45, 4077\u20134081 (1985).","journal-title":"Cancer Res."},{"key":"811_CR9","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1182\/blood-2015-01-621870","volume":"126","author":"N Jacque","year":"2015","unstructured":"Jacque, N. et al. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. Blood 126, 1346\u20131356 (2015).","journal-title":"Blood"},{"key":"811_CR10","doi-asserted-by":"publisher","first-page":"79722","DOI":"10.18632\/oncotarget.12944","volume":"7","author":"P Matre","year":"2016","unstructured":"Matre, P. et al. Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes. Oncotarget 7, 79722\u201379735 (2016).","journal-title":"Oncotarget"},{"key":"811_CR11","doi-asserted-by":"publisher","first-page":"35863","DOI":"10.18632\/oncotarget.16262","volume":"8","author":"RM Thompson","year":"2017","unstructured":"Thompson, R. M. et al. Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells. Oncotarget 8, 35863\u201335876 (2017).","journal-title":"Oncotarget"},{"key":"811_CR12","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1158\/1535-7163.MCT-18-0985","volume":"18","author":"NM Zacharias","year":"2019","unstructured":"Zacharias, N. M. et al. Assessing metabolic intervention with a glutaminase inhibitor in real-time by hyperpolarized magnetic resonance in acute myeloid leukemia. Mol. Cancer Ther. 18, 1937\u20131946 (2019).","journal-title":"Mol. Cancer Ther."},{"key":"811_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30396-3","volume":"13","author":"N Baran","year":"2022","unstructured":"Baran, N. et al. Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia. Nat. Commun. 13, 2801 (2022).","journal-title":"Nat. Commun."},{"key":"811_CR14","doi-asserted-by":"publisher","first-page":"4994","DOI":"10.1158\/1078-0432.CCR-21-1204","volume":"27","author":"JJ Harding","year":"2021","unstructured":"Harding, J. J. et al. A phase I dose-escalation and expansion study of telaglenastat in patients with advanced or metastatic solid tumors. Clin. Cancer Res. 27, 4994\u20135003 (2021).","journal-title":"Clin. Cancer Res."},{"key":"811_CR15","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.V100.3.791","volume":"100","author":"M Albitar","year":"2002","unstructured":"Albitar, M. et al. Myelodysplastic syndrome is not merely \u2018preleukemia\u2019. Blood 100, 791\u2013798 (2002).","journal-title":"Blood"},{"key":"811_CR16","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1002\/cncr.22570","volume":"109","author":"X Ma","year":"2007","unstructured":"Ma, X., Does, M., Raza, A. & Mayne, S. T. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 109, 1536\u20131542 (2007).","journal-title":"Cancer"},{"key":"811_CR17","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux, P. et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 10, 223\u2013232 (2009).","journal-title":"Lancet Oncol."},{"key":"811_CR18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1182\/blood-2006-05-021162","volume":"109","author":"H Kantarjian","year":"2007","unstructured":"Kantarjian, H. et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109, 52\u201357 (2007).","journal-title":"Blood"},{"key":"811_CR19","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","volume":"29","author":"T Prebet","year":"2011","unstructured":"Prebet, T. et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J. Clin. Oncol. 29, 3322\u20133327 (2011).","journal-title":"J. Clin. Oncol."},{"key":"811_CR20","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1002\/cncr.25247","volume":"116","author":"E Jabbour","year":"2010","unstructured":"Jabbour, E. et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer 116, 3830\u20133834 (2010).","journal-title":"Cancer"},{"key":"811_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6901","volume":"6","author":"M Gerstung","year":"2015","unstructured":"Gerstung, M. et al. Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes. Nat. Commun. 6, 5901 (2015).","journal-title":"Nat. Commun."},{"key":"811_CR22","doi-asserted-by":"publisher","first-page":"101564","DOI":"10.1016\/j.jbc.2022.101564","volume":"298","author":"TT Nguyen","year":"2022","unstructured":"Nguyen, T. T., Ramachandran, S., Hill, M. J. & Cerione, R. A. High-resolution structures of mitochondrial glutaminase C tetramers indicate conformational changes upon phosphate binding. J. Biol. Chem. 298, 101564 (2022).","journal-title":"J. Biol. Chem."},{"key":"811_CR23","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1158\/1078-0432.CCR-14-3378","volume":"22","author":"J Benito","year":"2016","unstructured":"Benito, J. et al. Hypoxia-activated prodrug TH-302 targets hypoxic bone marrow niches in preclinical leukemia models. Clin. Cancer Res. 22, 1687\u20131698 (2016).","journal-title":"Clin. Cancer Res."},{"key":"811_CR24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.cmet.2018.06.003","volume":"28","author":"A Daemen","year":"2018","unstructured":"Daemen, A. et al. Pan-cancer metabolic signature predicts co-dependency on glutaminase and de novo glutathione synthesis linked to a high-mesenchymal cell state. Cell Metab. 28, 383\u2013399 (2018).","journal-title":"Cell Metab."},{"key":"811_CR25","doi-asserted-by":"publisher","first-page":"19611","DOI":"10.1073\/pnas.1117773108","volume":"108","author":"DR Wise","year":"2011","unstructured":"Wise, D. R. et al. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of \u03b1-ketoglutarate to citrate to support cell growth and viability. Proc. Natl Acad. Sci. USA 108, 19611\u201319616 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"811_CR26","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","volume":"18","author":"ME Figueroa","year":"2010","unstructured":"Figueroa, M. E. et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553\u2013567 (2010).","journal-title":"Cancer Cell"},{"key":"811_CR27","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3390\/cancers15020531","volume":"15","author":"J De Los Santos-Jimenez","year":"2023","unstructured":"De Los Santos-Jimenez, J. et al. Metabolic adjustments following glutaminase inhibition by CB-839 in glioblastoma cell lines. Cancers (Basel) 15, 531 (2023).","journal-title":"Cancers (Basel)"},{"key":"811_CR28","doi-asserted-by":"publisher","first-page":"5479","DOI":"10.1172\/JCI120156","volume":"128","author":"A Shastri","year":"2018","unstructured":"Shastri, A. et al. Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells. J. Clin. Invest. 128, 5479\u20135488 (2018).","journal-title":"J. Clin. Invest."},{"key":"811_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41591-018-0267-4","volume":"25","author":"J Chen","year":"2019","unstructured":"Chen, J. et al. Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level. Nat. Med. 25, 103\u2013110 (2019).","journal-title":"Nat. Med."},{"key":"811_CR30","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.cmet.2019.11.020","volume":"31","author":"HC Yoo","year":"2020","unstructured":"Yoo, H. C. et al. A variant of SLC1A5 is a mitochondrial glutamine transporter for metabolic reprogramming in cancer cells. Cell Metab. 31, 267\u2013283 (2020).","journal-title":"Cell Metab."},{"key":"811_CR31","doi-asserted-by":"publisher","first-page":"20322","DOI":"10.1002\/jcp.28632","volume":"234","author":"Y Li","year":"2019","unstructured":"Li, Y., Shao, H., Da, Z., Pan, J. & Fu, B. High expression of SLC38A1 predicts poor prognosis in patients with de novo acute myeloid leukemia. J. Cell. Physiol. 234, 20322\u201320328 (2019).","journal-title":"J. Cell. Physiol."},{"key":"811_CR32","doi-asserted-by":"publisher","first-page":"eabq5925","DOI":"10.1126\/sciadv.abq5925","volume":"8","author":"R Rais","year":"2022","unstructured":"Rais, R. et al. Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug. Sci. Adv. 8, eabq5925 (2022).","journal-title":"Sci. Adv."},{"key":"811_CR33","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1158\/1535-7163.MCT-22-0282","volume":"21","author":"Y Yokoyama","year":"2022","unstructured":"Yokoyama, Y., Estok, T. M. & Wild, R. Sirpiglenastat (DRP-104) induces antitumor efficacy through direct, broad antagonism of glutamine metabolism and stimulation of the innate and adaptive immune systems. Mol. Cancer Ther. 21, 1561\u20131572 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"811_CR34","doi-asserted-by":"publisher","first-page":"128321","DOI":"10.1016\/j.bmcl.2021.128321","volume":"50","author":"RD Gao","year":"2021","unstructured":"Gao, R. D. et al. Model studies towards prodrugs of the glutamine antagonist 6-diazo-5-oxo-l-norleucine (DON) containing a diazo precursor. Bioorg. Med. Chem. Lett. 50, 128321 (2021).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"811_CR35","doi-asserted-by":"publisher","first-page":"7186","DOI":"10.1021\/acs.jmedchem.7b00966","volume":"60","author":"MT Nedelcovych","year":"2017","unstructured":"Nedelcovych, M. T. et al. N-(pivaloyloxy)alkoxy-carbonyl prodrugs of the glutamine antagonist 6-diazo-5-oxo-l-norleucine (DON) as a potential treatment for HIV associated neurocognitive disorders. J. Med. Chem. 60, 7186\u20137198 (2017).","journal-title":"J. Med. Chem."},{"key":"811_CR36","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou, T. C. Drug combination studies and their synergy quantification using the Chou\u2013Talalay method. Cancer Res. 70, 440\u2013446 (2010).","journal-title":"Cancer Res."},{"key":"811_CR37","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1038\/s41375-022-01614-0","volume":"36","author":"SB Panina","year":"2022","unstructured":"Panina, S. B. et al. Novel mitochondria-targeting compounds selectively kill human leukemia cells. Leukemia 36, 2009\u20132021 (2022).","journal-title":"Leukemia"},{"key":"811_CR38","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1200\/JCO.2011.40.7379","volume":"30","author":"R Bejar","year":"2012","unstructured":"Bejar, R. et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J. Clin. Oncol. 30, 3376\u20133382 (2012).","journal-title":"J. Clin. Oncol."},{"key":"811_CR39","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg, P. et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89, 2079\u20132088 (1997).","journal-title":"Blood"},{"key":"811_CR40","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson, B. D. et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108, 419\u2013425 (2006).","journal-title":"Blood"},{"key":"811_CR41","doi-asserted-by":"publisher","first-page":"104221","DOI":"10.1016\/j.isci.2022.104221","volume":"25","author":"X Lu","year":"2022","unstructured":"Lu, X. et al. Metabolomics-based phenotypic screens for evaluation of drug synergy via direct-infusion mass spectrometry. iScience 25, 104221 (2022).","journal-title":"iScience"},{"key":"811_CR42","doi-asserted-by":"publisher","first-page":"6630","DOI":"10.1002\/jcp.30307","volume":"236","author":"SM Stanford","year":"2021","unstructured":"Stanford, S. M. et al. The low molecular weight protein tyrosine phosphatase promotes adipogenesis and subcutaneous adipocyte hypertrophy. J. Cell. Physiol. 236, 6630\u20136642 (2021).","journal-title":"J. Cell. Physiol."},{"key":"811_CR43","doi-asserted-by":"publisher","first-page":"D622","DOI":"10.1093\/nar\/gkab1062","volume":"50","author":"DS Wishart","year":"2022","unstructured":"Wishart, D. S. et al. HMDB 5.0: the Human Metabolome Database for 2022. Nucleic Acids Res. 50, D622\u2013D631 (2022).","journal-title":"Nucleic Acids Res."},{"key":"811_CR44","doi-asserted-by":"publisher","unstructured":"Tiziani, S. et al. Metabolomics data: glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes. Zenodo https:\/\/doi.org\/10.5281\/zenodo.7641622 (2023).","DOI":"10.5281\/zenodo.7641622"},{"key":"811_CR45","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cels.2018.11.005","volume":"8","author":"SL Wolock","year":"2019","unstructured":"Wolock, S. L., Lopez, R. & Klein, A. M. Scrublet: computational identification of cell doublets in single-cell transcriptomic data. Cell Syst. 8, 281\u2013291 (2019).","journal-title":"Cell Syst."},{"key":"811_CR46","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289\u20131296 (2019).","journal-title":"Nat. Methods"},{"key":"811_CR47","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888\u20131902 (2019).","journal-title":"Cell"},{"key":"811_CR48","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nbt.4314","volume":"37","author":"E Becht","year":"2019","unstructured":"Becht, E. et al. Dimensionality reduction for visualizing single-cell data using UMAP. Nat. Biotechnol. 37, 38\u201344 (2019).","journal-title":"Nat. Biotechnol."},{"key":"811_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27150-6","volume":"12","author":"M Buttner","year":"2021","unstructured":"Buttner, M., Ostner, J., Muller, C. L., Theis, F. J. & Schubert, B. scCODA is a Bayesian model for compositional single-cell data analysis. Nat. Commun. 12, 6876 (2021).","journal-title":"Nat. Commun."},{"key":"811_CR50","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"811_CR51","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1136\/jclinpath-2011-200039","volume":"64","author":"B Agarwal","year":"2011","unstructured":"Agarwal, B., Das, P., Naresh, K. N. & Borges, A. M. Angiogenic ability of metastatic squamous carcinoma in the cervical lymph nodes from unknown primary tumours. J. Clin. Pathol. 64, 765\u2013770 (2011).","journal-title":"J. Clin. Pathol."}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00811-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00811-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00811-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T06:03:14Z","timestamp":1729749794000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00811-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":51,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["811"],"URL":"https:\/\/doi.org\/10.1038\/s43018-024-00811-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2518774\/v1","asserted-by":"object"}]},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"assertion":[{"value":"26 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.V. has received research funding from Prelude, Ryvu, BMS, GSK, Incyte, Medpacto, Curis and Eli Lilly, is a scientific advisor for Stelexis, Aurigene, Acceleron and Celgene, receives honoraria from Stelexis, Aurigene and Janssen and holds equity in Stelexis and Clinstreet. K.S. is a current employee of Gilead Sciences, Inc. All work contributing to the paper was performed while at the University of Texas MD Anderson Cancer Center. N.J.S. has received consulting fees from Pfizer Inc., GSK, NKARTA, Autolus, Adaptive Biotechnologies and Sanofi and research funding from Takeda Oncology, Astellas Pharma Inc., Xencor, GSK, NextCure, Ascentage and Novartis. N.J.S. receives honoraria from Adaptive Biotechnologies, Amgen, Takeda, Pfizer Inc., Astellas Pharma Inc. and Sanofi. C.D.D. is a consultant and\/or on the advisory board of Abbvie, AstraZeneca, Astellas, BMS, Genentech, GenMab, GSK, Notable Labs, Rigel, Ryvu, Schrodinger and Servier. S. Konoplev is consultant for Cairo Diagnostics Laboratory. G.S.C. has stock options in privately held company Curis. M.R.G. reports research funding from Sanofi, Kite\/Gilead, Abbvie and Allogene; consulting for Abbvie and Allogene; advisory board for Bristol Myers Squibb, Arvinas and Johnson & Johnson; honoraria from BMS, Daiichi Sankyo and DAVA Oncology; and stock ownership of KDAc Therapeutics. S.D. is employed at Calithera. M.K. received research support from Calithera. U.S. has received research funding from GlaxoSmithKline, Bayer Healthcare, Aileron Therapeutics and Novartis; has received compensation for consultancy services and for serving on scientific advisory boards from GlaxoSmithKline, Bayer Healthcare, Celgene, Aileron Therapeutics, Stelexis Therapeutics and Pieris Pharmaceuticals; and has equity ownership in and has served on the board of directors of Stelexis Therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}